UK Backs Novartis Multiple Sclerosis Pill

Novartis’s multiple sclerosis pill Gilenya has been recommended for use on the UK’s publicly funded National Health Service, a welcome decision for the Swiss drugmaker regarding a potential blockbuster product whose safety profile has come into question.
The Wall Street Journal